Investor's Business Daily on MSN52m
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer DrugAstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...
Several of these commercialized cell therapies have emerged as top-selling drugs in the healthcare sector. For example, Gilead Sciences reported that Yescarta achieved sales exceeding USD 1.5 billion, ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
Public health groups raise concern on patent grant to promising, new HIV drug Patient and public health groups have raised concerns over a potential patent grant to Gilead Sciences for the HIV drug ...
Shanghai-based Fosun Pharmaceutical has acquired the remaining 50% stake in Fosun Kite Biotechnology from Kite Pharma for $27 ...
With rapid innovations in biotechnology, companies are developing groundbreaking therapies and diagnostic tools that address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback